Article

FDA approves new delivery system for IV antibiotic

The FDA recently approved a new delivery system for the antibioticcefoxitin, which is indicated for the treatment of urinary tractinfections, gynecologic infections (eg, pelvic inflammatorydisease), and a number of other common infections.

The FDA recently approved a new delivery system for the antibiotic cefoxitin, which is indicated for the treatment of urinary tract infections, gynecologic infections (eg, pelvic inflammatory disease), and a number of other common infections.

The Duplex Drug Delivery System is now the only ready-to-use IV drug delivery system available for cefoxitin therapy in the United States, according to its manufacturer, B. Braun Medical Inc. Its FDA approval follows supply shortages caused by the recent discontinuation of Baxter Healthcare’s cefoxitin for injection (Mefoxin).

B. Braun said it is currently accepting calls to assist customers affected by the supply shortage. The company can be reached at 800-227-2862.

Related Videos
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Alternative treatments and patient communication for genitourinary syndrome of menopause
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Expert discusses genitourinary syndrome of menopause guidelines
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Anna Myers, CNP, answers a question during a Zoom video interview
Urology CNP discusses sensitivity in communication, physical exam
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Drug costs | Image Credit: © pixelrobot - stock.adobe.com
Urologist discusses drug cost savings, price transparency
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Related Content
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025
April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD
Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD
"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
FDA grants marketing authorization to at-home diagnostic test for STIs
March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke
The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL
"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
© 2025 MJH Life Sciences

All rights reserved.